Shanghai Mabgeek Biotech.Co.Ltd
14
4
6
0
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
0.0%
0 terminated/withdrawn out of 14 trials
43%
6 trials in Phase 3/4
0%
0 of 0 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14)
A Study of MG-K10 in Chronic Spontaneous Urticaria
Role: lead
A Phase III Study of MG-K10 in Adolescents With Moderate-to-Severe Atopic Dermatitis
Role: lead
A Study to Evaluate the Efficacy and Safety of MG-K10 in Participants Who Have Atopic Dermatitis
Role: lead
A Study of MG-K10 Humanized Monoclonal Antibody Injection in Subjects With Atopic Dermatitis
Role: lead
Study of MG-ZG122 Humanized Monoclonal Antibody in Asthma Subjects
Role: lead
Phase III Clinical Study of MG-K10 Humanized Mab Injection in Subjects With Prurigo Nodularis
Role: lead
Phase II/III Seamless Clinical Study of MG-K10 Humanized Monoclonal Antibody Injection in Treatment of Seasonal Allergic Rhinitis
Role: lead
Clinical Trial of MG-K10 in Stage III of Moderate to Severe Asthma
Role: lead
IB/IIa Study of MG-K10 in Adolescent Moderately Severe Patients
Role: lead
Clinical Study of MG-K10 Humanized Monoclonal Antibody Injection in Healthy Adult Subjects
Role: lead
Study of MG-K10 Humanized Monoclonal Antibody Injection in Patients With Atopic Dermatitis
Role: lead
A Study of MG-K10 in Subjects With Atopic Dermatitis
Role: lead
Single Dose Clinical Trial of MG-ZG122 in Chinese Healthy Adult Subjects
Role: lead
A Study of MG-K10 in Subjects With Asthma
Role: lead
All 14 trials loaded